2024 Funded Researchers

7/1/2022 - 6/30/2026 | $792,000

Targeting Cancer Stem Cells to Induce Anti-Tumor Immunity in Small Cell Lung Cancer

9/1/2020-8/31/2024 | $784,000

Mechanisms of Enhancer Activation during changes in Cell State

1/1/2024 - 12/31/2026 | $660,000

ACS Diversity in Cancer Research

1/1/2022 - 12/31/2025 | $842,000

Harnessing Tryptophan Dependency to Dissect and Disable Liver Cancer

11/1/23 - 10/31/25 | $300,000

Targeting MTAP-Deficient Cancers by Inhibiting MAT2A Induction

1/1/2024 - 12/31/2027 | $792,000

Enhancing Oncolytic Virotheraphy Through Inhibition of Novel FACT-ETS-1 Antiviral Response Pathway

9/1/2020 - 5/31/24 | $437,400

Optimizing Emergency Department Use for Adults Newly-diagnosed with Cancer

1/1/2023 -12/31/2026 | $752,000

Regulation of Cancer Cell Migration Through the Purine-Dependent Control of Serine Synthesis

1/1/2020 - 12-31-2024 | $792,000

Regulation of mTORC1 by Glutamine

1/1/2021 - 12/31/2024 | $792,000

Epigenetic Regulation of Breast Tumor Initiation

4/1/2021 - 3/31/2025 | $791,000

Define Metabolically Distinct Immune-evasive Metastasis Initiating Cells

1/1/24-12/31/25 | $300,000

The Joint Influence of Health Insurance and Sick Leave on Colon Cancer Screening

7/1/2021 - 6/30/2025 | $792,000

Regulation of Hepatocellular Carcinoma by NOD-Like Receptors